胰激肽原酶对糖尿病早期肾病患者肾功能的影响

目的研究胰激肽原酶对糖尿病早期肾病患者肾功能的影响。方法将46例2型糖尿病患者随机分成两组，治疗组（胰激肽原酶组）26例，对照组20例，两组均行综合性治疗，治疗组同时加用胰激肽原酶治疗，监测3个疗程前后空腹血糖、餐后2h血糖、糖化血清蛋白、总胆固醇、甘油三酯、血压、血液流变学各指标，24h尿蛋白（24hUALB）定量，并观察其肾组织高峰到达时间、10min残留率及15min残留率等指标的变化情况。结果胰激肽原酶组可使2型糖尿病患者血液流变学各指标明显降低（P〈0．01），血脂、血压下降亦显著（P〈0．05），15min残留率明显下降（左右肾均P〈0．01），10min残留率亦明显减少（左右肾均P〈0．05），24hUALB定量降低（P〈0．01）。结论胰激肽原酶可有效地降低血液粘稠度，抑制血小板聚集，降低血脂、血压，改善糖尿病患者的分泌和排泄功能，减少尿蛋白的排出，促进糖尿病早期肾脏病变恢复。

Clinical impacts of kallidinogenase on renal functionin early diabetic kidney disease

Objective To investigate the impact of kallidinogenase on renal function in early diabetic kidney disease. Methods Forty - six cases of patients suffered from type 2 diabetes mellitus were divided into two groups at random in which 26 cases served as observed group accepted kallidinogenasemedicationadditionally and the other 20 cases received comprehensive medication simultaneously. Fasting blood glucose, 2 hours postprandial blood glucose, glycosylated serum protein, total cholesterol, triglycerides, blood pressure, items of hemorheology, 24 - hour urine protein, time span of peak time, residual rate for 10 minutes and 15 minutes were record and compared before and after three cases of medication. Results Indexes of hemorheology decreased significantly after 3 causes of medication （ P 〈 0.01 ）, blood lipid, and blood pressure also declined significantly（ P 〈 0.01 ）. 15 minutes residual rate decreased significantly and 10 minutes residual rate also declined（ P 〈 0.01 ）. The 24 - hour urinary protein reduced significantly（ P 〈 0.01 ）. Conclusions Kallidinogenase can effectively decrease blood viscosity and platelet aggregation, lowering blood lipids and blood pressure, improving the secretion and excretion function, reducing the discharge of urine protein and promote the resumption of diabetic kidney disease in early stage.